Audubon Bioscience

Growth Stage

Company offering biospecimen procurement services and more that earned $4+ million in 2020 revenue Invest


Raised to Date: Raised: $314,921

Aggregate Commitments $



Start Date


Close Date


Min. Goal


Max. Goal


Min. Investment


Security Type

Convertible Note

Funding Type




Valuation Cap


Discount Rate


Rolling Commitments $



Reporting Date


Days Remaining


% of Min. Goal


% of Max. Goal


Likelihood of Max
Avg. Daily Raise


Log in or create a free account today to gain access to KingsCrowd analytics.

Houston, Texas


Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity


Business Type


Audubon Bioscience, with a valuation cap of $8 million, is raising funds on MicroVentures. It is a biotechnology company that offers biospecimen procurement services to pharma companies and government healthcare organizations. The client companies use the services to access clinical data and history for their research. Dr. Rostyslav Semikov founded Audubon Bioscience in 2016. The current crowdfunding campaign of the company, with a minimum raise of $50,000 and a maximum raise of $250,000, will target equipment purchases, future wages, and general working capital. Audubon Bioscience generated a revenue of $4.19 million in 2020, up 131% from a year before. The company has clinical sites in twelve countries and over 40 customers across the public and private sectors.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 03/03/2021
Log in or create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual


$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Staff Picks (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual


$41.67 /month
billed annually
Full site access including Merlin ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by Merlin ratings
Company specific Merlin rating and risk assessment
Get Merlin Annual
Already a member? Log in here.


Analyst Report


In 2020 alone, companies produced, tested, and began to produce a vaccine for a completely new virus on a mass scale. This process represents a momentous breakthrough in vaccine sciences — and potentially for medical science as a whole. Such advances don’t come easily. Medical science involves a huge and complicated process to reach from the lab to the patient, from experimentation to mass production. 

One crucial link in the medical development chain is biobanking. In order to develop and target medical treatments, clinics and laboratories require samples: human blood, tissue, and so on. Biobanks collect and distribute these samples for purposes of ethical research and analysis that respect donor privacy. A new and increasingly successful competitor in this essential space is Audubon Bioscience. Based in New Orleans and Houston with sites in 12 countries, Audubon procures human samples and provides them to pharmaceutical, biotech, and diagnostic companies in the appropriate locations and contexts. It also collects records to provide mass-scale medical data in areas like pathology, demographics, and treatment.

With an emphasis on providing materials for cancer research, Audubon has seen its revenue and team grow significantly since its founding in 2016, now including a staff of 70 and having contracts with 40 clients including the CDC and the National Cancer Institute. Audubon plans to launch an e-commerce platform in 2022 to expand its customer base.

Audubon Bioscience’s current MicroVentures raise has been rated a Top Deal by the KingsCrowd investment team.


In order to expand its already expansive team, form new partnerships, and purchase additional equipment, Audubon is raising capital through a convertible note. Audubon’s valuation cap for this round comes in at $8 million with a 20% discount rate. While both of these numbers would give Audubon a good rating on its own, the real winner here is its revenue multiple. The $8 million valuation represents just under twice Audubon’s revenue in 2020, which is an absolutely stellar multiple for a company in the healthcare space. As a result, the company’s price score is its highest across all five metrics.


Audubon’s target market is both a strong selling point and the main point of concern in this investment. Biobanking is absolutely lucrative and is growing at an incredible rate. In 2019, the industry was expected to reach a size of $57.67 billion by 2026. However, owing to acceleration from the COVID-19 pandemic, the market was actually valued at $65.9 billion in 2020 and is expected to grow at a CAGR of 6.2% until 2028. This steady growth should provide Audubon with ample room to expand.

Unfortunately, Audubon is far from the only player taking advantage of this large market. One of the largest competitors in this space is Biobank Graz, a publicly-owned nonprofit that provides millions of samples and is one of the largest biobanks in Europe. Other competitors include UK Biobank and Brooks Life Sciences, both of which have been involved in COVID-19 research. Nevertheless, Audubon’s presence in various countries across the world represents a global need, and due to the size of the market, it is likely that this will not be a winner-takes-all space. Thus, Audubon Bioscience’s market score is strong.


Audubon is headed up by an experienced team and a founder who brings expertise from many parts of the world. Doctor Rostyslav Semikov holds a master’s degree in global health science from the prestigious Oxford University, which he obtained after getting his MD from Zaporozhye State Medical University in Ukraine. After spending almost a decade in Ukraine working in general practice and medical management, Semikov served as head of development for East West Biopharma in Switzerland before starting up Audubon in the US. He also has a few years of experience working in various operational and business development positions, all prior to his work at East West Biopharma.

Audubon President Maurice Cabirac has been with the company almost from the beginning. Audubon represents something of an industry shift for Cabirac, who spent several decades working in management roles in mechanical contracting companies like ARC Mechanical Contractors in Vermont and New Hampshire as well as Mechanical Construction Company in Louisiana. Biobanking is an entirely different industry from Cabirac’s previous experience, though it seems he has adapted his expertise for business development and company coordination purposes.

Finally, Marie Cabirac is Audubon’s Finance Director. Cabirac worked for McDonough Marine Services, which provides barges for moving construction equipment. Like President Cabirac, Finance Director Cabirac worked in her chosen field for several decades, the pair of them coming onboard to Audubon with divergent experiences now applied to the unfamiliar space of biobanking. While a leadership team with somewhat higher levels of medical credentials would be preferable, the team’s overall experience appears to have been sufficient to get Audubon off the ground. In addition to the leadership team, Audubon employs a broad assortment of managerial and consulting employees with varying levels of experience.

Audubon Bioscience’s team score is above average in reflection of its team’s leadership skills balanced against the lack of entrepreneurial experience and limited medical expertise.


In a competitive market, Audubon needs to set itself apart, and it has been successful. While the company enjoys no patent protections for its operations and analysis, it has invested the capital required to surmount biobanking’s formidable barriers to entry. The major advantage Aduobon has over competitors is the gathered patient data and history it can provide to customers. This data includes demographic and treatment data as well as follow-up longitudinal data — meaning Audubon allows customers to analyze long-term and mass-scale trends in addition to individual samples. Key competitors in the space — such as Discovery Life Sciences and Cureline — focus heavily on providing biospecimens and laboratory services. By supplementing its biobanking services with large amounts of medical data, Audubon has distinguished itself and carved out a service that only it provides. The company’s differentiators score is high as a result.


Unlike many startups we cover using Regulation Crowdfunding to raise capital, Audubon has actually reached a profitable stage of development. Last year, Audubon took in $106,447 in net income. While this is a decrease from $175,505 the year before, it is reflective of huge investments in cost of goods, business travel, and development. In terms of raw revenue, the company took in $4.19 million in 2020, up from $1.81 million the year before. This kind of consistent, growing revenue is extremely encouraging and indicates that Audubon has developed a successful business model. Therefore, its performance score is quite high.

Bearish Outlook

As with any startup, investing in Audubon does entail certain risks. The company faces well-established competitors in biobanking, which are numerous and likewise multinational. If its data services do not draw substantial appeal from clients, Audubon could struggle to carve out a large enough niche to survive. While the startup has seen significant and growing success in its operations, it has had to make massive investments in materials and people to secure its existing contracts and partnerships.

To that end, Audubon faces the same risks and exposures of any business. As the company is a healthcare company, it faces stringent regulation of patient data, any violation of which could result in massive censure and penalties. Given the company’s early traction, it is unlikely to entirely crash and burn, but its high costs mean it must secure as much of its target market as possible. The launch of its e-commerce platform may prove useful in this regard.

Bullish Outlook

Audubon Bioscience seems ready to go big. With market penetration across several countries and infrastructure investments made to set up an efficient global delivery network, Audubon is proving a competent and ethical partner in a rapidly-expanding space. The advance of medical science is likely to continue at a rapid pace, and human samples are the foundation upon which that industry is built. In the coming years, Audubon is likely to continue to see revenue growth as it secures further partnerships and opens its e-commerce site. The company is well-positioned to eventually become a major contender in global biobanking. This raise represents a promising opportunity for investors to become a part of that success.

Executive Summary

Audubon Bioscience is an emerging biobanking company. Starting out in New Orleans and moving to Houston in 2018, the company has engaged 40 customers and established 100 sites in 12 countries. Through collecting patient samples like tissue and blood, analyzing them, and delivering them to labs and clinics, Audubon’s services represent an essential step in the medical research process. The company also provides substantial amounts of medical data to better enable in-depth research and experiments for its clients.

Audubon’s revenue growth has been consistent and impressive, and the company scores quite highly in all metrics. While its chosen market is a tightly-contested one, the company’s valuation is extremely advantageous to investors, and its team is solid and experienced. Despite massive expenses, Audubon has begun to see net profits and is well-positioned to establish itself as a major name in biobanking. For these reasons, the KingsCrowd investment team gave Audubon Bioscience a Top Deal rating.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written by Benjamin Potts.

Other Deals

Covira Surgical on StartEngine 2021

The biotech company is focused on novel therapeutic alternatives to reduce post-surgical infections. The procedures of Covira Surgical leverage the…

Valuation: $9,987,500
Min Investment: $250
Industry: Healthcare & Pharmaceuticals
Raised $185,557 of $1,070,000 max

Fluo Labs on StartEngine 2021

The medical device of Fluo Labs uses light therapy to relieve patients of their allergy symptoms without the use of…

Valuation: $12,000,000
Min Investment: $250
Industry: Healthcare & Pharmaceuticals
Raised $84,504 of $3,800,000 max

Actipulse Neuroscience on Republic 2021

The business also aims to bring non-invasive treatment to patients’ homes. Adrien Chatillon founded Actipulse Neuroscience in June 2019. The…

Valuation Cap: $10,000,000
Min Investment: $100
Industry: Healthcare & Pharmaceuticals
Raised $92,426 of $1,070,000 max

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Audubon Bioscience on MicroVentures

Follow company

Follow Audubon Bioscience on MicroVentures